SCHEMBL14073309

SCHEMBL14073309

O=C1COc2ccc(CNC(=O)c3cnc4ccccc4c3)cc2N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.59
▸ MAOA P21397 1/20 0.56
▸ PARP1 P09874 3/20 0.53
▸ ALDH1A1 P00352 1/20 0.52
▸ NAMPT P43490 1/20 0.51
▸ MMP8 P22894 5/20 0.51
▸ MMP13 P45452 5/20 0.51
▸ HDAC3 O15379 1/20 0.50
▸ HDAC1 Q13547 1/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ PSMD14 O00487 1/20 0.48
▸ COPS5 Q92905 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ METTL3 Q86U44 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ HTR1D P28221 1/20 0.45
▸ HTR1B P28222 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073359 0.88 TSHR (0.63) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073344 0.85 TSHR (0.55) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073579 0.83 KMT2A (0.60) ALDH1A1MAPTUSP2POLBBLM
SCHEMBL14073306 0.82 USP2 (0.59) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073392 0.82 TSHR (0.56) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073276 0.82 TSHR (0.66) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14072985 0.81 TSHR (0.85) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073338 0.81 TSHR (0.64) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073152 0.81 TSHR (0.59) TSHRMAOAPARP1ALDH1A1MMP8
SCHEMBL14073336 0.81 TSHR (0.67) TSHRMAOAPARP1ALDH1A1MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 TSHR 4343/4885MAOA 137/4885PARP1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback